QQ客服 官方微博 反馈留言

浏览/检索结果: 共5条，第1-5条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial 期刊论文 2019, 卷号: 25, 期号: 3, 页码: E153-E158 作者:  Yang, Renchi;  Sun, Jing;  Zhao, Yongqiang;  Wang, Xuefeng;  Wu, Depei 收藏  |  浏览/下载：14/0  |  提交时间：2020/01/03 BAY 81-8973  Chinese  clinical trial  factor VIII  haemophilia  prophylaxis   BAY 81-8973 Demonstrates Comparable Efficacy During Prophylaxis Irrespective of The Assay Determining Potency 会议论文 HAEMOPHILIA, 2015-01-01 作者:  Saxena, K.;  Kavakli, K.;  Kitchen, S.;  Oldenburg, J.;  Yang, R. 收藏  |  浏览/下载：8/0  |  提交时间：2020/01/04 Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) 期刊论文 2015, 卷号: 13, 期号: 3, 页码: 360-369 作者:  Kavakli, K.;  Yang, R.;  Rusen, L.;  Beckmann, H.;  Tseneklidou-Stoeter, D. 收藏  |  浏览/下载：3/0  |  提交时间：2020/01/13 factor VIII  hemophilia A  prophylaxis  recombinant proteins  therapeutic equivalency   BAY 81-8973 Demonstrates Comparable Efficacy During Prophylaxis Irrespective of The Assay Determining Potency 期刊论文 2015, 卷号: 21, 期号: ,SI, 页码: 31-32 作者:  Saxena, K.;  Kavakli, K.;  Kitchen, S.;  Oldenburg, J.;  Yang, R. 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13 Superiority of prophylaxis versus on-demand therapy with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973): LEOPOLD II study results 期刊论文 2014, 卷号: 20, 期号: ,SI, 页码: 94-95 作者:  Kavakli, Kaan;  Yang, Renchi;  Rusen, Luminita;  Beckmann, Horst;  Tseneklidou-Stoeter, Despina 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/13